{"id":10616,"date":"2024-09-08T16:00:00","date_gmt":"2024-09-08T20:00:00","guid":{"rendered":"https:\/\/cov19longhaulfoundation.org\/?p=10616"},"modified":"2024-08-30T07:24:48","modified_gmt":"2024-08-30T11:24:48","slug":"safety-and-efficacy-of-low-dose-naltrexone-in-a-long-covid-cohort-an-interventional-pre-post-study","status":"publish","type":"post","link":"https:\/\/cov19longhaulfoundation.org\/?p=10616","title":{"rendered":"Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study."},"content":{"rendered":"\n<p class=\"has-small-font-size\"><a>O&#8217;Kelly B\u00a0<sup>1,2<\/sup><\/a>,\u00a0<a>Vidal L\u00a0<sup>2<\/sup><\/a>,\u00a0<a>McHugh T\u00a0<sup>2<\/sup><\/a>,\u00a0et. al. Brain, Behavior, &amp; Immunity &#8211; Health,\u00a003 Jul 2022, 24:100485, <a href=\"https:\/\/doi.org\/10.1016\/j.bbih.2022.100485\">https:\/\/doi.org\/10.1016\/j.bbih.2022.100485<\/a>\u00a0PMID: 35814187\u00a0PMCID: PMC9250701<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"article--abstract--header\">Abstract&nbsp;<\/h2>\n\n\n\n<h4 class=\"wp-block-heading\">Background<\/h4>\n\n\n\n<p>Up to 37.7% of patients experience symptoms beyond 12 weeks after infection with SARS-CoV-2. To date care for people with long covid has centred around multidisciplinary rehabilitation, self care and self pacing. No pharmacotherapy has been shown to be beneficial.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Methods<\/h4>\n\n\n\n<p>In this single centre interventional pre post study, the safety of Low Dose Naltrexone (LDN) was explored in patients with Post COVID-19 Syndrome (PCS), defined by NICE as patients with ongoing symptoms 12 or more weeks after initial infections with SARS-CoV-2 where alternative explanation for symptoms cannot be found. Patients were recruited through a Post COVID clinic, had a baseline quality of life questionnaire in symmetrical Likert format, were prescribed 2 months (1&nbsp;mg&nbsp;month one, 2&nbsp;mg&nbsp;month two) of LDN and repeated the same questionnaire at the end of the second month. Patients were monitored to adverse events.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Findings<\/h4>\n\n\n\n<p>In total 52 patients participated of whom 40(76.9%) were female. The median age was 43.5 years(IQR 33.2-49). Healthcare workers represented the largest occupational cohort n&nbsp;=&nbsp;16(34.8%). The median time from diagnosis of COVID-19 until enrolment was 333 days (IQR 171-396.5). Thirty-eight participants (73.1%) were known to commence LDN, two of whom (5.3%) stopped taking LDN post commencement due to new onset diarrhoea and also described fatigue. In total 36(69.2%) participants completed the questionnaire at the end of the two-month period. Improvement was seen in 6 of 7 parameters measured; recovery from COVID-19, limitation in activities of daily living, energy levels, pain levels, levels of concentration and sleep disturbance (p&nbsp;\u2264&nbsp;0.001), improvement in mood approached but was not significant (p&nbsp;=&nbsp;0.054).<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Conclusions<\/h4>\n\n\n\n<p>LDN is safe in patients with PCS and may improve well-being and reduce symptomatology in this cohort. Randomised control trials are needed to further explore this.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>O&#8217;Kelly B\u00a01,2,\u00a0Vidal L\u00a02,\u00a0McHugh T\u00a02,\u00a0et. al. Brain, Behavior, &amp; Immunity &#8211; Health,\u00a003 Jul 2022, 24:100485, https:\/\/doi.org\/10.1016\/j.bbih.2022.100485\u00a0PMID: 35814187\u00a0PMCID: PMC9250701 Abstract&nbsp; Background Up to 37.7% of patients experience symptoms beyond 12 weeks after [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":10711,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1093,101,309,886,416,949,561,592],"tags":[],"class_list":["post-10616","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-activities-of-daily-living","category-covid-19","category-memory","category-naltrexone","category-pain","category-sleep-disturbance","category-symptoms-covid-19","category-treatments"],"_links":{"self":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/10616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10616"}],"version-history":[{"count":1,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/10616\/revisions"}],"predecessor-version":[{"id":10617,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/10616\/revisions\/10617"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/media\/10711"}],"wp:attachment":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}